Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19

- In combination, the two monoclonal antibodies demonstrated a 70% relative reduction in persistently high viral load at day 7 compared to placebo - INDIANAPOLIS and SAN FRANCISCO and LONDON , March 29, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc.